CIRM’s ongoing struggle with financial conflicts of interest

The California Institute for Regenerative Medicine (CIRM), a $12 billion state agency, continues to grapple with financial conflicts of interest stemming from its governance model. Board member Haifaa Abdulhaq, a Fresno physician appointed in January 2021, secured a $9 million grant in 2024 for a cellular therapy program she had advocated for since joining the board. Abdulhaq resigned in February 2024, three years after her appointment, following the award approval. The agency’s structure has long drawn criticism. Created in 2004 via ballot initiative, CIRM grants board seats to institutions eligible for funding, including Stanford and multiple University of California campuses. The top 10 grantees—excluding Scripps Research—have collectively received $2.8 billion of CIRM’s $4.5 billion in awards. A 2011 National Academy of Medicine study, commissioned by CIRM for $700,000, identified these arrangements as a ‘significant problem,’ citing ‘inherent’ conflicts that compromise decision-making independence. While CIRM rules prohibit board members from voting on grants to their own institutions, they influence broader funding strategies and concept plans. Abdulhaq did not vote on her grant’s concept plan, and both she and CIRM denied wrongdoing, stating she followed policies. Former CIRM general counsel James Harrison, who helped draft the agency’s founding law, acknowledged the conflicts as ‘inherent’ to CIRM’s design. The situation highlights systemic tensions between oversight and self-interest. Taxpayer dollars fund research at elite institutions while board members—often tied to those same institutions—shape priorities. Critics argue the model undermines public trust, despite legal compliance. Abdulhaq’s case reignites debates over whether CIRM’s governance can reconcile its dual role as regulator and funder.